GLP-1 drug for early type 1 diabetes
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study tests whether a GLP-1 receptor agonist (a type of medicine that helps control blood sugar and appetite) can improve metabolic health in people with early type 1 diabetes. It may be an option if you have already taken teplizumab to delay the disease or were recently diagnosed with type 1 diabetes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 to 50 years old
- Your body mass index (BMI) is between 18 and 31 (for adults) or in the 5th to 95th percentile for your age (for children)
- You have either Stage 2 type 1 diabetes (at least two diabetes-related antibodies and abnormal blood sugar levels) and have already received TZIELD® (teplizumab), or you have been newly diagnosed with early Stage 3 type 1 diabetes (within the last 8 weeks)
- You are not taking any other diabetes medications, including insulin, at the start of the study
- You have no history of pancreatitis, gastroparesis, or a family history of medullary thyroid cancer
- You are not pregnant or going through menopause, and you do not smoke
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a weekly semaglutide injection (a GLP-1 drug) to a closed-loop insulin system can help reduce the need for carb counting in people with type 1 diabetes. It aims to improve blood sugar control and make diabetes management easier.
This trial tests a medication (called a GLP-1 receptor agonist) to see if it can help people in the earliest stage of type 1 diabetes keep their insulin-making cells working longer. It might help delay the need for insulin injections.
This trial tests a new GLP-1 receptor agonist to improve blood sugar control in people with type 2 diabetes. It may be an option if you haven't used a similar drug in the last three months and your medical records are complete.
This study tests whether a GLP-1 medication (a type of drug that helps with weight loss) can safely and effectively help young adults with type 1 diabetes who also have obesity. It aims to see if adding this treatment to insulin can improve weight and blood sugar control.
This study tests whether semaglutide, a medicine that helps control blood sugar and reduce weight, can benefit adults with type 1 diabetes who are overweight. If you qualify, you may receive the drug or a placebo, and the study team will monitor your health closely.
This study tests if adding LY3457263 helps lower blood sugar in people with type 2 diabetes who are already taking a stable dose of semaglutide or tirzepatide. You will be randomly assigned to get either LY3457263 or a placebo.
Hear when a new Type 1 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.